MDCXM&A

Medicus proposes $135 million pre-money SkinJect business combination with undisclosed SPAC

Medicus Pharma Ltd.'s wholly owned subsidiary SkinJect, Inc. entered a non-binding letter of intent with an undisclosed special purpose acquisition company for a proposed business combination that contemplates a $135 million pre-money enterprise valuation for SkinJect and a concurrent equity financing. The SPAC would acquire 100% of SkinJect in exchange for newly issued common shares of the combined company, with Medicus seeking to retain majority economic and voting ownership of a separately listed company. The...

Published November 4, 2026 at 5:51 PM ESTMedicus Pharma Ltd.SEC filing

Share this story

Key takeaways

5-7 ranked factual English bullets

Key metrics

SkinJect pre-money enterprise valuation

$135 million

SkinJect equity to be acquired by SPAC

100%

Anticipated business combination completion

First half of 2027

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

All MDCX coverage

MDCXM&A

Medicus proposes $135 million SkinJect business combination and concurrent financing

VIVKM&A

Vivakor reports proposed $40 million Direct Midstream acquisition and airport project

IONQM&A

IonQ Completes Elisity Acquisition

GMHSM&A

Gamehaus to acquire 56% stake in Techforge/Anamana for $26.6 million

Follow MDCX in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert